Pirfenidone enhances the efficacy of combined radiation and sunitinib therapy

Biochemical and Biophysical Research Communications

Volumn 462, Issue 2, 2015, Pages 138-143

  Choi, Seo Hyun ^a   Nam, Jae Kyung ^a   Jang, Junho ^a   Lee, Hae June ^a   Lee, Yoon Jin ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

Lewis lung carcinoma; Pirfenidone; Radiotherapy; Sunitinib; Transforming growth factor

Indexed keywords

COLLAGEN; PIRFENIDONE; SUNITINIB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRIDONE DERIVATIVE; PYRROLE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CAPILLARY DENSITY; DRUG EFFICACY; ENDOTHELIUM CELL; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; TUMOR MICROENVIRONMENT; ANIMAL; CARCINOMA, LEWIS LUNG; DRUG EFFECTS; METABOLISM; MICROVASCULATURE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION DOSE; RADIATION RESPONSE; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; COLLAGEN; COMBINED MODALITY THERAPY; INDOLES; MICE; MICROVESSELS; PYRIDONES; PYRROLES; RADIATION TOLERANCE; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84929834046     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.04.107     Document Type: Article

References (35)

1. T. Le Chevalier, R. Arriagada, and E. Quoix Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients J. Natl. Cancer Inst. 83 1991 417 423
2. A.W. Goolden Radiation cancer: a review with special reference to radiation tumours in the pharynx, larynx, and thyroid Br. J. Radiol. 30 1957 626 640
3. E.A. Kleibeuker, M.A. Ten Hooven, and K.C. Castricum Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction Cancer Med. (2015 Mar 31), http://dx.doi.org/10.1002/cam4.441 [Epub ahead of print]. PMID: 25828633
4. S. Faivre, G. Demetri, and W. Sargent, et al. Molecular basis for sunitinib efficacy and future clinical development Nat. Rev. Drug. Discov. 6 2007 734 745
5. M.A. Socinski The current status and evolving role of sunitinib in non-small cell lung cancer J. Thorac. Oncol. 3 2008 S119 S123
6. J. Kao, C.T. Chen, and C.C. Tong, et al. Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial Target Oncol. 9 2014 145 153
7. C.C. Tong, E.C. Ko, and M.W. Sung, et al. J. Kao Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases PLoS One 7 2012 e36979
8. C. Nieder, N. Wiedenmann, and N.H. Andratschke Radiation therapy plus angiogenesis inhibition with bevacizumab: rationale and initial experience Rev. Recent Clin. Trials 2 2007 163 168
9. T.Y. Seiwert, J.K. Salama, and E.E. Vokes The concurrent chemoradiation paradigm-general principles Nat. Clin. Pract. Oncol. 4 2007 86 100
10. P. Wachsberger, R. Burd, and A.P. Dicker Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction Clin. Cancer Res. 9 2003 1957 1971
11. E.J. Abel, S.H. Culp, and N.M. Tannir, et al. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib Eur. Urol. 60 2011 1273 1279
12. C. Seidel, M. Fenner, and A.S. Merseburger, et al. Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients World J. Urol. 29 2011 355 360
13. M. Kim, S.H. Choi, and Y.B. Jin, et al. The effect of oxidized low-density lipoprotein (ox-LDL) on radiation-induced endothelial-to-mesenchymal transition Int. J. Radiat. Biol. 89 2013 356 363
14. Y.J. Lee, H.J. Lee, and S.H. Choi, et al. Soluble HSPB1 regulates VEGF-mediated angiogenesis through their direct interaction Angiogenesis 15 2012 229 242
15. L.Q. Chow, and S.G. Eckhardt Sunitinib: from rational design to clinical efficacy J. Clin. Oncol. 25 2007 884 896
16. A. Prasanna, M.M. Ahmed, and M. Mohiuddin, et al. Exploiting sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy J. Thorac. Dis. 6 2014 287 302
17. A.J. Schueneman, E. Himmelfarb, and L. Geng, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models Cancer Res. 63 2003 4009 4016
18. J. Kao, S. Packer, and H.L. Vu, et al. Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response Cancer 115 2009 3571 3580
19. R.J. Motzer, T.E. Hutson, and P. Tomczak, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N. Engl. J. Med. 356 2007 115 124
20. S. Biswas, M. Guix, and C. Rinehart, et al. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression J. Clin. Invest 117 2007 1305 1313
21. H.C. Dancea, M.M. Shareef, and M.M. Ahmed Role of radiation-induced TGF-beta signaling in Cancer therapy Mol. Cell. Pharmacol. 1 2009 44 56
22. D.M. Gilkes, S. Bajpai, and C.C. Wong, et al. Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis Mol. Cancer Res. 11 2013 456 466
23. D.M. Gilkes, P. Chaturvedi, and S. Bajpai, et al. Collagen prolyl hydroxylases are essential for breast cancer metastasis Cancer Res. 73 2013 3285 3296
24. P. Lu, V.M. Weaver, and Z. Werb The extracellular matrix: a dynamic niche in cancer progression J. Cell. Biol. 196 2012 395 406
25. P. Chen, M. Cescon, and P. Bonaldo Collagen VI in cancer and its biological mechanisms Trends Mol. Med. 19 2013 410 417
26. M. Loeffler, J.A. Kruger, and A.G. Niethammer Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake J. Clin. Invest. 116 2006 1955 1962
27. F. Lotti, A.M. Jarrar, and R.K. Pai, et al. Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A J. Exp. Med. 210 2013 2851 2872
28. A. Affolter, I. Schmidtmann, and W.J. Mann, et al. Cancer-associated fibroblasts do not respond to combined irradiation and kinase inhibitor treatment Oncol. Rep. 29 2013 785 790
29. R.A. Rosiello, and W.W. Merrill Radiation-induced lung injury Clin. Chest Med. 11 1990 65 71
30. C. Chargari, F. Riet, and M. Mazevet, et al. Complications of thoracic radiotherapy Presse. Med. 42 2013 e342 351
31. J.N. Finkelstein, C.J. Johnston, and R. Baggs, et al. Early alterations in extracellular matrix and transforming growth factor beta gene expression in mouse lung indicative of late radiation fibrosis Int. J. Radiat. Oncol. Biol. Phys. 28 1994 621 631
32. B.A. Karimi-Shah, and B.A. Chowdhury Forced vital capacity in idiopathic pulmonary fibrosis-FDA review of pirfenidone and nintedanib N. Engl. J. Med. 372 2015 1189 1191
33. E.S. Kim, and G.M. Keating Pirfenidone: a review of its use in idiopathic pulmonary fibrosis Drugs 75 2015 219 230
34. P. Spagnolo, N. Sverzellati, and G. Rossi, et al. Idiopathic pulmonary fibrosis: an update Ann. Med. 47 2015 15 27
35. K. Togami, A. Miyao, and K. Miyakoshi, et al. Efficient delivery to human lung fibroblasts (WI-38) of pirfenidone incorporated into liposomes modified with truncated basic fibroblast growth factor and its inhibitory effect on collagen synthesis in idiopathic pulmonary fibrosis Biol. Pharm. Bull. 38 2015 270 276